39 related articles for article (PubMed ID: 23728394)
1. Early development of PAT-SM6 for the treatment of melanoma.
Hensel F; Eckstein M; Rosenwald A; Brändlein S
Melanoma Res; 2013 Aug; 23(4):264-75. PubMed ID: 23728394
[TBL] [Abstract][Full Text] [Related]
2. The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78.
Rosenes Z; Mulhern TD; Hatters DM; Ilag LL; Power BE; Hosking C; Hensel F; Howlett GJ; Mok YF
PLoS One; 2012; 7(9):e44927. PubMed ID: 23028685
[TBL] [Abstract][Full Text] [Related]
3. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.
Irie RF; Ollila DW; O'Day S; Morton DL
Cancer Immunol Immunother; 2004 Feb; 53(2):110-7. PubMed ID: 14564483
[TBL] [Abstract][Full Text] [Related]
4. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4.
Nguyen N; Sharma A; Nguyen N; Sharma AK; Desai D; Huh SJ; Amin S; Meyers C; Robertson GP
Cancer Prev Res (Phila); 2011 Feb; 4(2):248-58. PubMed ID: 21097713
[TBL] [Abstract][Full Text] [Related]
5. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
Rasche L; Duell J; Castro IC; Dubljevic V; Chatterjee M; Knop S; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
Haematologica; 2015 Mar; 100(3):377-84. PubMed ID: 25637055
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis.
Liu R; Li X; Gao W; Zhou Y; Wey S; Mitra SK; Krasnoperov V; Dong D; Liu S; Li D; Zhu G; Louie S; Conti PS; Li Z; Lee AS; Gill PS
Clin Cancer Res; 2013 Dec; 19(24):6802-11. PubMed ID: 24048331
[TBL] [Abstract][Full Text] [Related]
7. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
[TBL] [Abstract][Full Text] [Related]
8. The role of B-1 cells in cancer progression and anti-tumor immunity.
Rodríguez-Zhurbenko N; Hernández AM
Front Immunol; 2024; 15():1363176. PubMed ID: 38629061
[TBL] [Abstract][Full Text] [Related]
9. Grp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis.
Spaan CN; de Boer RJ; Smit WL; van der Meer JH; van Roest M; Vermeulen JL; Koelink PJ; Becker MA; Go S; Silva J; Faller WJ; van den Brink GR; Muncan V; Heijmans J
Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37643866
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the dark side of glucose-regulated protein 78 (GRP78) in cancers and other human pathology: a systematic review.
Akinyemi AO; Simpson KE; Oyelere SF; Nur M; Ngule CM; Owoyemi BCD; Ayarick VA; Oyelami FF; Obaleye O; Esoe DP; Liu X; Li Z
Mol Med; 2023 Aug; 29(1):112. PubMed ID: 37605113
[TBL] [Abstract][Full Text] [Related]
11. Endoplasmic Reticulum Stress and Cancer: Could Unfolded Protein Response Be a Druggable Target for Cancer Therapy?
Bonsignore G; Martinotti S; Ranzato E
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675080
[TBL] [Abstract][Full Text] [Related]
12. Hydra-Elastin-like Polypeptides Increase Rapamycin Potency When Targeting Cell Surface GRP78.
Avila H; Yu J; Boddu G; Phan A; Truong A; Peddi S; Guo H; Lee SJ; Alba M; Canfield E; Yamamoto V; Paton JC; Paton AW; Lee AS; MacKay JA
Biomacromolecules; 2022 Aug; 23(8):3116-3129. PubMed ID: 35786858
[TBL] [Abstract][Full Text] [Related]
13. Physiological Roles of the Autoantibodies to the 78-Kilodalton Glucose-Regulated Protein (GRP78) in Cancer and Autoimmune Diseases.
Gonzalez-Gronow M; Pizzo SV
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740249
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effect of caudatin in diethylnitrosamine‑induced hepatocarcinogenesis in rats.
Song J; Ding W; Liu B; Liu D; Xia Z; Zhang L; Cui L; Luo Y; Jia X; Feng L
Mol Med Rep; 2020 Aug; 22(2):697-706. PubMed ID: 32626931
[TBL] [Abstract][Full Text] [Related]
15. Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target.
Ge R; Kao C
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31766302
[TBL] [Abstract][Full Text] [Related]
16. Strong and sustained activation of the anticipatory unfolded protein response induces necrotic cell death.
Livezey M; Huang R; Hergenrother PJ; Shapiro DJ
Cell Death Differ; 2018 Oct; 25(10):1796-1807. PubMed ID: 29899383
[TBL] [Abstract][Full Text] [Related]
17. Targeting the unfolded protein response in cancer.
Ojha R; Amaravadi RK
Pharmacol Res; 2017 Jun; 120():258-266. PubMed ID: 28396092
[TBL] [Abstract][Full Text] [Related]
18. Development of Novel Immunotherapies for Multiple Myeloma.
Al-Hujaily EM; Oldham RA; Hari P; Medin JA
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618026
[TBL] [Abstract][Full Text] [Related]
19. Immunoglubolin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii).
Ujvari B; Hamede R; Peck S; Pemberton D; Jones M; Belov K; Madsen T
Sci Rep; 2016 Apr; 6():25093. PubMed ID: 27126067
[TBL] [Abstract][Full Text] [Related]
20. Melanoma and the Unfolded Protein Response.
Sykes EK; Mactier S; Christopherson RI
Cancers (Basel); 2016 Feb; 8(3):. PubMed ID: 26927180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
